View Post

Rare Patient Voice: Research opportunity for Breast Cancer (metastatic) patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Details: 30 min online survey Please sign up at the link below to receive an email invite to the survey.  Compensation $50 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay …

View Post

Tucatinib Combination Demonstrates Multiple Positive Responses in HER2-Positive Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Tony Berberabe, MPH From: targetedonc.com Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB (NCT02614794) trial. Lead author Nancy Lin, MD, and colleagues reported that the combination doubled the intracranial objective …

View Post

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases

In Clinical Studies News by Barbara Jacoby

By: Nancy Lin, MD From: targetedonc.com Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases Nancy U. Lin, MD, associate professor of medicine at Harvard Medical School; associate chief of the Division of Breast …

View Post

Ask the Expert: 8 Things to Consider About Treatment for MBC

In In The News by Barbara Jacoby

From: healthline.com 1. What treatments are available for postmenopasal women with MBC The metastatic breast cancer (MBC) treatment plan your doctor will recommend depends on whether the tumors have receptors for estrogen or progesterone or elevated levels of human epidermal growth factor receptor 2 (HER2). These are known as a tumor’s biologic subtype. There are various targeted therapies for each …

View Post

Immutep’s partner, EOC Pharma, to continue advancing Efti in breast cancer

In Clinical Studies News by Barbara Jacoby

From: pharmiweb.com Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing Efti (designated as EOC202 in China) in metastatic breast cancer. The confirmation follows EOC Pharma’s analysis of the recently reported Progression Free Survival (PFS) data, including subgroup …

View Post

Trastuzumab Deruxtecan Approved in Japan for HER2+ Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-positive unresectable or recurrent breast cancer who have had prior chemotherapy and are refractory or intolerant to standard treatments. The approval is based on findings from the phase II DESTINY-Breast01 trial, in which the …

View Post

Samsung Bioepis’ biosimilar breast cancer treatment scores FDA’s nod

In Clinical Studies News by Barbara Jacoby

From: koreabiomed.com Samsung Bioepis said Friday that the U.S. Food and Drug Administration has granted sales approval for Ontruzant 420mg, a trastuzumab biosimilar (Original: Herceptin). Ontruzant treats patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer. Its original, Herceptin, is one of the world’s most purchased medicines, with an annual sale of 7.2 trillion won ($5.7 billion) …

View Post

Becoming Your Own Best Advocate and Building a Dream Team to Thrive

In In The News by Barbara Jacoby

By: Kristie L. Kahl From: curetoday.com At CURE’s Educated Patient Breast Cancer Summit, Stephanie Seban shared the ways a patient can become their own best advocate to thrive through their breast cancer journey. Patients with breast cancer must be their own best advocates, building their own personal dream team to thrive throughout their journey, Stephanie Seban said in her keynote …